Drug Profile
Shark cartilage powder - Lane Labs
Alternative Names: BeneFinLatest Information Update: 10 Sep 2003
Price :
$50
*
At a glance
- Originator Lane Labs
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer; Breast cancer; Prostate cancer; Solid tumours
Most Recent Events
- 10 Apr 2000 The US FDA has demanded that Lane Labs be ordered to surrender its rights to 3 trademarked brandnames, including Benefin®
- 15 Dec 1999 US Justice Department files complaint alleging unlawful marketing of BeneFin
- 06 Aug 1999 Investigation in Solid tumours in Chile (PO)